Con: Hetastarch Should be Avoided for Volume Expansion in Cardiac Surgery Patients

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 32, Issue 1, 2018, Pages 576-579

  Sacchet Cardozo, Fabrizzio ^a   Stoicea, Nicoleta ^a   Joseph, Nicholas ^a,b   Dewhirst, Elisabeth ^a   Essandoh, Michael ^a  

^a Division of Cardiothoracic and Vascular Anesthesiology   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Acute kidney injury; Cardiac surgery; Coagulopathy; Colloids; Crystalloids; Hydroxyethyl starch

Indexed keywords

GLUCOSE POLYMER; HETASTARCH;

ACUTE KIDNEY FAILURE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; COLLOID; CRITICALLY ILL PATIENT; CRYSTALLOID; EFFECT SIZE; FUNCTIONAL DISEASE; HEART SURGERY; HUMAN; HYPOCOAGULABILITY; KIDNEY DYSFUNCTION; MOLECULAR WEIGHT; NOTE; PLASMA CLEARANCE; PRIORITY JOURNAL; PUBLISHING; RENAL REPLACEMENT THERAPY; RESUSCITATION; RISK FACTOR; VISCOELASTICITY;

EID: 85008675554     PISSN: 10530770     EISSN: 15328422     Source Type: Journal    
DOI: 10.1053/j.jvca.2016.07.028     Document Type: Note

References (21)

1. Zbrozek, A., Magee, G., Cost of bleeding in trauma and complex cardiac surgery. Clin Ther 379 (2015), 1966–1974.
2. Haydock, M.D., Kruger, C., Willcox, T., et al. Does removing mannitol and Voluven from the priming fluid of the cardiopulmonary bypass circuit have clinical effects?. J Extra Corpor Technol 46 (2014), 77–83.
3. Bayer, O., Schwarzkopf, D., Doenst, T., et al. Perioperative fluid therapy with tetrastarch and gelatin in cardiac surgery–A prospective sequential analysis. Crit Care Med 41 (2013), 2532–2542.
4. Zarychanski, R., Abou-Setta, A.M., Turgeon, A.F., et al. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: A systematic review and meta-analysis. JAMA 309 (2013), 678–688.
5. Lagny, M.G., Roediger, L., Koch, J.N., et al. Hydroxyethyl starch 130/0.4 and the risk of acute kidney injury after cardiopulmonary bypass: A single-center retrospective study. J Cardiothorac Vasc Anesth 30 (2016), 869–875.
6. Skhirtladze, K., Base, E.M., Lassnigg, A., et al. Comparison of the effects of albumin 5%, hydroxyethyl starch 130/0.4 6%, and Ringer's lactate on blood loss and coagulation after cardiac surgery. Br J Anaesth 112 (2014), 255–264.
7. Navickis, R.J., Haynes, G.R., Wilkes, M.M., Effect of hydroxyethyl starch on bleeding after cardiopulmonary bypass: A meta-analysis of randomized trials. J Thorac Cardiovasc Surg 144 (2012), 223–230.
8. Kim, H.J., Kim, S.Y., Oh, M.J., Anaphylaxis induced by hydroxyethyl starch during general anesthesia. A case report. Korean J Anesthesiol 63 (2012), 260–262.
9. U.S. Department of Health and Human Services. FDA Safety Communication: Boxed Warning on increased mortality and severe renal injury, and additional warning on risk of bleeding, for use of hydroxyethyl starch solutions in some settings. U.S. Food and Drug Administration 2013. Available at: http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm358271.htm. Accessed April 13, 2016.
10. Hartog, C.S., Reuter, D., Loesche, W., et al. Influence of hydroxyethyl starch (HES) 130/0.4 on hemostasis as measured by viscoelastic device analysis: A systematic review. Intensive Care Med 3711 (2011), 1725–1737.
11. Bellmann, R., Feistritzer, C., Wiedermann, C.J., Effect of molecular weight and substitution on tissue uptake of hydroxyethyl starch: A meta-analysis of clinical studies. Clin Pharmacokinet 51 (2012), 225–236.
12. Hartog, C.S., Kohl, M., Reinhart, K., A systematic review of third-generation hydroxyethyl starch (HES 130/0.4) in resuscitation: Safety not adequately addressed. Anesth Analg 112 (2011), 635–645.
13. Williams, P., Yang, K., Kershaw, G., et al. The effects of haemodilution with hydroxyethyl starch 130/0.4 solution on coagulation as assessed by thromboelastography and platelet receptor function studies in vitro. Anaesth Intensive Care 43 (2015), 734–739.
14. Wiedermann, C.J., Joannidis, M., Mortality after hydroxyethyl starch 130/0.4 infusion: An updated meta-analysis of randomized trials. Swiss Med Wkly, 142, 2012, w13656.
15. Navickis, R.J., Haynes, G.R., Wilkes, M.M., Tetrastarch in cardiac surgery: Error, confounding and bias in a meta-analysis of randomized trials. Crit Care, 19, 2015, 187.
16. Kim, J.Y., Joung, K.W., Kim, K.M., et al. Relationship between a perioperative intravenous fluid administration strategy and acute kidney injury following off-pump coronary artery bypass surgery: An observational study. Crit Care, 19, 2015, 350.
17. Bethlehem, I., Wierda, K., Visser, C., et al. Influence of two colloidal extracorporeal primes on coagulation of cardiac surgical patients: A prospectively randomized open-label pilot trial. J Extra Corpor Technol 46 (2014), 293–299.
18. Cho, J.E., Shim, J.K., Song, J.W., et al. Effect of 6% hydroxyethyl starch 130/0.4 as a priming solution on coagulation and inflammation following complex heart surgery. Yonsei Med J 55 (2014), 625–634.
19. Gillies, M.A., Habicher, M., Jhanji, S., et al. Incidence of postoperative death and acute kidney injury associated with i.v. 6% hydroxyethyl starch use: Systematic review and meta-analysis. Br J Anaesth 112 (2014), 25–34.
20. Englberger, L., Suri, R.M., Li, Z., et al. Clinical accuracy of RIFLE and Acute Kidney Injury Network (AKIN) criteria for acute kidney injury in patients undergoing cardiac surgery. Crit Care, 15, 2011, R16.
21. Lau, G., Wald, R., Sladen, R., et al. Acute kidney injury in cardiac surgery and cardiac intensive care. Semin Cardiothorac Vasc Anesth 19 (2015), 270–287.